Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 2, 2016CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], its novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of hemophilia B.
02 Mar 2016 In clinical trials, IDELVION maintained factor IX activity levels above 5 percent over 14 days, resulting in a median annualized spontaneous bleeding rate (AsBR) of 0.00 IDELVION, CSL...
-
Feb 29, 2016Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with hemophilia B.
29 Feb 2016 Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting...
-
Feb 24, 2016Global biotherapeutics leader CSL Behring today announced an enhancement to its manufacturing process for Privigen® with the addition of the Ig IsoLo® step.
24 Feb 2016 Global biotherapeutics leader CSL Behring today announced an enhancement to its manufacturing process for Privigen® with the addition of the Ig IsoLo® step. Ig IsoLo is an...
-
Feb 23, 2016Global biotherapeutics leader CSL Behring today announced an increase in the global supply of Privigen® as the first export has been shipped from a new state-of-the-art manufacturing facility in Broadmeadows, Melbourne, Australia.
23 Feb 2016 Global biotherapeutics leader CSL Behring today announced an increase in the global supply of Privigen® as the first export has been shipped from a new state-of-the-art manufacturing...
-
Feb 2, 2016CSL Behring’s U.S. locations raised more than $1 million in 2015 for a wide array of charities, setting a new company record.
02 Feb 2016 CSL Behring’s U.S. locations in King of Prussia and Kankakee, Il., and its subsidiary, CSL Plasma headquartered in Boca Raton, Fla., raised more than $1 million in 2015 for a wide...